Cutaneous cryptococcosis.
Cutaneous cryptococcosis occurs in 10 to 15% of patients with cryptococcosis. Because the cutaneous crytpococcosis may precede clinical signs of central nervous system disease, early recognition may lead to more successful outcomes. This article reviews the mycology, epidemiology, pathology, clinical manifestations, and treatment of this disease, focusing primarily on the cutaneous aspects.
Hernandez
A D
AD
Sarasota Memorial Hospital, Florida.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D003453:Cryptococcosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000473:pathology; D003455:Cryptococcus neoformans / Q000302:isolation & purification; D003881:Dermatomycoses / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000473:pathology; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance
D000666:Amphotericin B; D005437:Flucytosine